CD26: A Multi-Purpose Pharmacological Target

Title:CD26: A Multi-Purpose Pharmacological Target

Volume: 9 Issue: 2

Author(s): Formica Vincenzo, Tesauro Manfredi, Cardillo Carmine and Roselli Mario

Affiliation:

Keywords: CD26, colorectal cancer, dipeptidyl peptidase 4, glucagon-like petide-1, stromal cell-derived factor-1.

Abstract: CD26 is a widely expressed transmembrane glycoprotein with peptidase activity in its extracellular domain and which regulates multiple biological processes.

It acts mainly as catabolic enzyme for a number of circulating proteins involved in common pathological conditions such as diabetes and cardiovascular disease and may represent a target to modulate bioavailability of crucial substrates.

The aim of the present review is to summarize data regarding CD26-based pharmacological interventions. Four main subtopics were identified:1) CD26 as the target of pharmacological inhibitors to increase bioavailability of glucagon-like petide-1 (GLP-1) and hence to enhance GLP-1 glucose-lowering activity in diabetic patients; 2) role of CD26 in the physiology and pathology of the cardiovascular system; 3) the adverse prognostic value of CD26 expression on cancer cells; 4) CD26 down-regulation on lymphocytes as a mechanism of TGF-beta immunomodulation.

Cite this article as:

Vincenzo Formica, Manfredi Tesauro, Carmine Cardillo and Mario Roselli, CD26: A Multi-Purpose Pharmacological Target, Current Clinical Pharmacology 2014; 9 (2) . https://dx.doi.org/10.2174/1574884708666131111201654

DOI https://dx.doi.org/10.2174/1574884708666131111201654	Print ISSN 1574-8847
Publisher Name Bentham Science Publisher	Online ISSN 2212-3938